CRIPTO Antibody [Biotin]
Novus Biologicals, part of Bio-Techne | Catalog # NB100-1598B
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human, Mouse
Applications
Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Western Blot
Label
Biotin
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
A synthetic peptide made to an N-terminal portion of mouse Cripto1 (between residues 1-50). [UniProt# P51865]
Localization
Membrane-bound
Marker
Embryonic Stem Cell Marker
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for CRIPTO Antibody [Biotin]
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Cripto
Long Name
Teratocarcinoma-derived Growth Factor/Cripto Growth Factor
Alternate Names
CFC-2, TDGF-1, TDGF1
Gene Symbol
CRIPTO
Additional Cripto Products
Product Documents for CRIPTO Antibody [Biotin]
Product Specific Notices for CRIPTO Antibody [Biotin]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...